Human medicines European public assessment report (EPAR): Inlyta, axitinib, Date of authorisation: 03/09/2012, Revision: 17, Status: Authorised

Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 25 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 25 February 2025, 11:00 (CET) to 25 February 2025, 11:45 (CET)

Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 11 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 February 2025, 11:00 (CET) to 11 February 2025, 11:45 (CET)

Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 4 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 February 2025, 11:00 (CET) to 4 February 2025, 11:45 (CET)

Human medicines European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene), thalidomide, Date of authorisation: 16/04/2008, Revision: 33, Status: Authorised

Innovation Task Force (ITF) briefing meeting request form

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 08/02/2018, Revision: 13, Status: Authorised

Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)

Human medicines European public assessment report (EPAR): Yellox, bromfenac, Date of authorisation: 18/05/2011, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma), dabigatran etexilate, Date of authorisation: 19/02/2024, Revision: 5, Status: Authorised